DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Higher Dose of Ramipril Versus Addition of Telmisartan-Ramipril in Hypertension and Diabetes

Information source: Institut de Recherches Cliniques de Montreal
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension; Type 2 Diabetes; Albuminuria

Intervention: ramipril (Drug); ramipril-telmisartan (Drug)

Phase: Phase 3

Status: Terminated

Sponsored by: Institut de Recherches Cliniques de Montreal

Official(s) and/or principal investigator(s):
Pierre Larochelle, MD PhD FRCPC, Principal Investigator, Affiliation: Institut de Recherches Cliniques de Montreal

Summary

The purpose of this study is to determine if a dose of ramipril combined with a normal dose of telmisartan 80 mg will be more effective than ramipril 20 mg in reducing microalbuminuria in hypertensive patients with diabetes.

Clinical Details

Official title: Comparison of a Higher Dose of Ramipril to the Addition of Telmisartan 80 mg+Ramipril 10 mg in Patients With Hypertension and Diabetes

Study design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study

Primary outcome: Microalbuminuria

Secondary outcome:

Plasma renin

plasma angiotensin

plasma aldosterone

plasma catecholamines

oxydative stress

diastolic blood pressure

systolic blood pressure

Detailed description: The purpose of this study is to determine the effects of ramipril 10 mg and telmisartan 80 mg versus ramipril 20 mg in patients with diabetes type II, hypertension and microalbuminuria (Urinary-albuminuria creatinine ratio of 2. 0 to 25 mg/mmol) on

1. Microalbuminuria

2. Blood pressure (systolic, diastolic and ABPM), Renin-angiotensin system, Catecholamines, Oxydative stress

3. Comparison at 4, 8 and 12 weeks with addition of hydrochlorothiazide 12. 5 mg if BP over 130/80 mmHg

Eligibility

Minimum age: 18 Years. Maximum age: 80 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Male or female over the age of 18 years

- Diastolic blood pressure (DBP) greater tha 80 mmHg and less than 104 mmHg

- Type II diabetes on diet or oral hypoglycemic agents with a hemoglobin A1C (HbA1C)

less than 0. 080

- UA ratio albumin: creatinine 2. 0 to 25 mg/mmol

Exclusion Criteria:

- DBP > 104 mmhg

- Woman not surgically sterile or menopausal.

- Premenopausal women whoo are not surgically sterile or who are not practicing

acceptable means of birth control and do not agree to submit to periodic pregnancy tests.

- Known or secondary forms of hypertension.

- Intolerance to angiotensin (AT) 1 receptor blockers or angiotensin-converting enzyme

(ACE) inhibitors.

- Hepatic or renal dysfunction. Creatinine > 150 umol or enzymes greater than 2 times

upper limit of normal.

- Hemodynamically significant renal artery stenosis, renal artery stenosis on a solitary

kidney, post-renal transplant or with only one kidney.

- Uncorrected volume depletion.

- Biliary obstructive disorders.

- NYHA functional class congestive heart failure (CHF) III-IV.

- Coronary heart disease needing pharmacological therapy.

- Stroke within the preceding six months.

- Percutaneous transluminal coronary angioplasty (PTCA) within the preceding three

months.

- History of angioedema.

- Sustained ventricular tachycardia, atrial fibrillation, or other clinically relevant

cardiac arrhythmias as determined by the clinical investigator.

- Second or third degree AV block, left bundle branch block or any clinically relevant

conduction abnormality as determined by the clinical investigator.

- Hypertrophic obstructive cardiomyopathy, aortic stenosis, hemodynamically relevant

stenosis of aortic or mitral valve.

- Administration of digoxin.

- Patients with a fasting glucose greater than 7. 0

- History of drug or alcohol dependency.

- Use of antihypertensive agents such as diuretics, ACE inhibitors, angiotensin II

antagonists, alpha-blockers, beta-blockers, calcium channel antagonists, direct vasodilators that cannot be stopped for the trial.

- Administration of other non-antihypertensive medications known to affect blood

pressure (e. g. oral corticosteroids, monoamine oxidase [MAO] inhibitors, nitrates) at any time during the trial.

- Chronic use of salt substitutes containing potassium chloride; potassium supplements;

extreme dietary restrictions.

- Uncorrected sodium depletion as defined by a serum sodium level less than 135 mEq/L.

- Clinically significant hyperkalemia as defined by serum potassium level greater than

5. 2 mEq/L. Clinically significant hypokalemia as defined by serum potassium level less than 3. 0 mEq/L.

- Patients receiving any investigational therapy within one month of signing the

informed consent form.

- Known hypersensitivity to any component of telmisartan, ramipril or

hydrochlorothiazide.

- Any other clinical condition which, in the opinion of the principal investigator,

would not allow safe completion of the protocol and safe administration of trial medication.

- Blood donation in the preceding 1 month.

Locations and Contacts

Institut de Recherches Cliniques de Montreal, Montreal, Quebec J4X 1J3, Canada
Additional Information

Starting date: August 2006
Ending date: June 2007
Last updated: November 7, 2007

Page last updated: June 20, 2008

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012